FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate

 Vaccine candidate expressing S-only protein produced higher serum antibodies than construct expressing both S and N in NHP study

Phase II clinical trial with S-only candidate to begin in 2H21

Development of this and other S-only constructs will proceed in parallel with that of S+N construct, as previously announced

https://finance.yahoo.com/news/fda-clears-vaxarts-ind-application-120000515.html